Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
Welcome to the calm before the Covid-19 storm.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.